A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

Cancer Chemotherapy and Pharmacology
Manabu ShiozawaSoichiro Morinaga

Abstract

A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer. The aim of this study was to determine the efficacy and safety of combining irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Irinotecan was administered as an intravenous infusion at a dose of 120 mg/m(2) on day 1 and 15. And S-1 was administered orally on days 1-14 of a 28-day cycle. S-1 was given orally at a dose that did not exceed 40 mg/m(2) based BSA: BSA < 1.25 m(2), 40 mg twice daily; 1.25-1.5 m(2), 50 mg twice daily, and BSA > 1.5 m(2), 60 mg twice daily, for 14 consecutive days. A total of 38 patients were enrolled. An intent-to-treat analysis showed a complete response and partial response to occur in 13.2% and 50.0%, respectively. The disease control rate was 84.2%. The median progression-free survival and overall survival were 10.0 months and 29.1 months, respectively. The rates of grade 3/4 toxicity over 4 cycles were the following: neutropenia, 15.8%; leucopenia, 7.9%; anorexia, 15.8%; diarrhea, 10.5%. IRIS is an effective, well tolerated and convenient treatment regimen for patients with advanced colorectal cancer.

References

Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-analysis Group In CancerE Levy
Jul 14, 2001·The New England Journal of Medicine·D J SargentR L Schilsky
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergS Wadler
Oct 13, 2001·The New England Journal of Medicine·D J SargentG Francini
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J MackayD Cunningham
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melina Verso, Giancarlo Agnelli
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C J A Punt
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M M BornerUNKNOWN Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe ColucciUNKNOWN Gruppo Oncologico Dell'Italia Meridionale
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C-H KöhneUNKNOWN European Organisation for Research and Treatment of Cancer Gastrointestinal Group
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GotoK Shirao
Nov 1, 2008·Journal of Cancer Research and Clinical Oncology·Manabu ShiozawaYukio Sugimasa

❮ Previous
Next ❯

Citations

Aug 7, 2012·Expert Opinion on Pharmacotherapy·Taroh Satoh, Yuh Sakata
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Yuji MiyamotoHideo Baba
May 10, 2016·Expert Opinion on Pharmacotherapy·J J M Kwakman, C J A Punt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

© 2021 Meta ULC. All rights reserved